- For Print
- January 22, 2007
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that on January 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) received a marketing authorization approval for the anti-epileptic agent Inovelon® (rufinamide) indicated as adjunctive therapy in Lennox-Gastaut Syndrome (LGS) from the European Commission (EC).
Eisai Ltd. submitted the marketing authorization application for Inovelon® in March, 2005 to the European Medicines Agency through the centralized procedure. In November, 2006, the company received a positive opinion by the Committee for Medicinal Products for Human Use, which was ratified by EC at this time.
Inovelon® is a structurally novel compound that acts as a broad-spectrum anticonvulsant. The data used for approval by EC this time was based on the result from a clinical trial (double-blind, placebo-controlled, randomized, parallel-group trial), which studied the drug's safety and efficacy in adjunctive treatment of LGS, a severe form of epilepsy that develops in early childhood. As a result of the trial, Inovelon® exhibited significant reduction in seizure frequency compared to the placebo.
Eisai is currently enhancing its neurology franchise which includes Aricept® (donepezil) for treatment of Alzheimer's disease and anti-epilepsy agent Zonegran® (zonisamide). With the approval of Inovelon®, the company expects to make further contributions in fulfilling the needs of patients and improving benefits to patients and their families.
[Please see the following note for the product information of Inovelon® approved by EC and the description of LGS]
< Note to Editors >
About Inovelon®
Inovelon® is a structurally novel compound that acts as a broad-spectrum anticonvulsant originally discovered and developed by Novartis Pharma AG. Eisai signed an in-licensing agreement for the global rights of the compound with Novartis in February 2004. In October 2004, the drug is granted for an orphan status by EC for adjunctive treatment of LGS, a severe form of epilepsy that develops in early childhood.
Product Information
- Generic Name : rufinamide
- Dosage : 100 mg tablet, 200 mg tablet, 400 mg tablet
- Applied Indication :
Adjunctive treatment of seizures associated with Lennox-Gastaut
Syndrome (LGS) in patients 4 years and older
About Lennox-Gastaut Syndrome (LGS)
LGS is a severe form of generalized epilepsy that develops in early childhood caused by various brain disorders such as brain hemorrhage, encephalitis, developmental malformations of the brain, or metabolic abnormalities. Tonic seizures, where muscles contract continuously, along with developmental delay and behavioral problems, are the major symptoms associated with LGS. On the other hand, the most characteristic manifestation of LGS is a large variety of seizures, such as atonic seizures (sudden loss of muscle tone and consciousness, causing abrupt falls), and atypical absence (starting spells), and myoclonic (sudden muscle jerks). A surgical treatment may be employed, in case the symptoms are too difficult to manage with pharmacotherapy.
Today, an estimated number of 11,000 people in Western Europe (Austria, Denmark, Finland, France, Germany, Italy, Ireland, Spain, Sweden and UK) is said to be affected by LGS. Complete recovery, including freedom from seizures or normal development, is very unusual. There is a strong need for development of a new pharmaceutical medicine for this disorder.